X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27) 27
index medicus (25) 25
oncology (22) 22
aged (19) 19
female (18) 18
male (18) 18
chemotherapy (17) 17
middle aged (15) 15
cancer (14) 14
adult (13) 13
metastasis (10) 10
survival (10) 10
analysis (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
bevacizumab (7) 7
cancer therapies (7) 7
retrospective studies (7) 7
aged, 80 and over (6) 6
care and treatment (6) 6
patients (6) 6
radiotherapy (6) 6
trial (6) 6
colorectal cancer (5) 5
colorectal neoplasms - drug therapy (5) 5
medical prognosis (5) 5
pathology (5) 5
prognosis (5) 5
research (5) 5
temozolomide (5) 5
treatment outcome (5) 5
tumors (5) 5
colorectal neoplasms - pathology (4) 4
dosage and administration (4) 4
follow-up studies (4) 4
genes (4) 4
immunohistochemistry (4) 4
irinotecan (4) 4
neoplasm metastasis (4) 4
neoplasm staging (4) 4
pharmacology & pharmacy (4) 4
phase-ii (4) 4
receptor, erbb-2 - genetics (4) 4
survival rate (4) 4
1st-line treatment (3) 3
5-fluorouracil (3) 3
abridged index medicus (3) 3
adenocarcinoma (3) 3
adjuvant temozolomide (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
biomarkers, tumor - analysis (3) 3
biomarkers, tumor - metabolism (3) 3
brain metastases (3) 3
brain neoplasms - drug therapy (3) 3
breast cancer (3) 3
carcinoma (3) 3
cell biology (3) 3
cell lung-cancer (3) 3
cells (3) 3
cisplatin (3) 3
clinical study (3) 3
clinical trials (3) 3
colorectal carcinoma (3) 3
colorectal neoplasms - genetics (3) 3
elderly (3) 3
elderly-patients (3) 3
esophageal neoplasms - metabolism (3) 3
fluorouracil (3) 3
health aspects (3) 3
hematology (3) 3
immunotherapy (3) 3
kaplan-meier estimate (3) 3
malignant glioma (3) 3
management (3) 3
medicine & public health (3) 3
metastases (3) 3
mortality (3) 3
older people (3) 3
progression (3) 3
proteins (3) 3
radiation therapy (3) 3
receptor, erbb-2 - metabolism (3) 3
single-agent bevacizumab (3) 3
stomach neoplasms - pathology (3) 3
surgery (3) 3
survival analysis (3) 3
vascular endothelial growth factor (3) 3
activities of daily living (2) 2
adenocarcinoma - genetics (2) 2
adenocarcinoma - metabolism (2) 2
adenocarcinoma - pathology (2) 2
adjuvant treatment (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
biomarkers, tumor - genetics (2) 2
breast-cancer (2) 2
camptothecin - analogs & derivatives (2) 2
cancer patients (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 738 - 746
Journal Article
Human Pathology, ISSN 0046-8177, 2013, Volume 44, Issue 9, pp. 1804 - 1810
Journal Article
Human Pathology, ISSN 0046-8177, 2015, Volume 46, Issue 5, pp. 665 - 672
Journal Article
Cancer, ISSN 0008-543X, 06/1986, Volume 57, Issue 11, p. 2185
The pathologic and clinical findings of 50 patients aged 65 or older (median, 71.5 years) with non-Hodgkin's lymphomas (NHL) are reported. These patients... 
Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Female | Lymphoma - pathology | Male | Aged | Retrospective Studies | Lymphoma - mortality
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 692 - 692
Conference Proceeding
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, p. e84940
Objective: To explore genes of the killer-cell immunoglobulin-like receptor (KIR) and of the HLA ligand and their relationship with the outcome of metastatic... 
MHC CLASS-I | TUMOR-INFILTRATING LYMPHOCYTES | ACTIVATING KIR | DENDRITIC CELLS | NK CELLS | GOOD PROGNOSIS | MULTIDISCIPLINARY SCIENCES | NATURAL-KILLER-CELL | ANTITUMOR-ACTIVITY | HLA | CROSS-PRESENTATION | Leucovorin - administration & dosage | Multivariate Analysis | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | HLA Antigens - genetics | Genetic Variation | Neoplasm Metastasis | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | HLA-B Antigens - genetics | Camptothecin - analogs & derivatives | Receptors, KIR - genetics | Receptors, KIR - classification | Gene Frequency | Kaplan-Meier Estimate | Genotype | Treatment Outcome | Disease Progression | Receptors, KIR3DL1 - genetics | HLA Antigens - classification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Care and treatment | Immunogenetics | Chemotherapy | Analysis | Patient outcomes | Colorectal cancer | Genetic research | Leucovorin | Metastasis | Fluorouracil | Biological diversity | Cancer | Peptides | 5-Fluorouracil | Colorectal carcinoma | Genes | Cytotoxicity | Oncology | Multivariate analysis | Parameter identification | Cancer therapies | Metastases | Hepatitis | Lymphocytes | Surgery | Immunotherapy | Human immunodeficiency virus--HIV | Killer cell immunoglobulin-like receptors | Immune system | Antigens | Immunoglobulins | Potassium channels (inwardly-rectifying) | Dendritic cells | Genetic diversity | T cell receptors | Gene expression | Patients | Survival | Irinotecan | Genotyping | Medical prognosis | Predictions | Ligands | Histocompatibility antigen HLA | Tissue typing | HIV | Human immunodeficiency virus
Journal Article
Modern Pathology, ISSN 0893-3952, 11/2015, Volume 28, Issue 11, pp. 1481 - 1491
Journal Article
Journal Article
Molecular Neurobiology, ISSN 0893-7648, 2/2018, Volume 55, Issue 2, pp. 1396 - 1404
Journal Article